Qingdao Guofeng Group Huayang Parmaceutical Co. Ltd.

Primary objective: To evaluate the bioequivalence of the two preparations under topical conditions in healthy Chinese subjects, using diclofenac diethylamine emulsion (specification: 1% (20g:0.2g, calculated as diclofenac sodium)) from GSK Consumer Healthcare Schweiz AG as the reference preparation and diclofenac diethylamine emulsion (1% (20g:0.2g, calculated as diclofenac sodium)) developed by Qingdao Baiyang Pharmaceutical Co., Ltd. as the test preparation. Secondary objectives: 1) To evaluate the safety of the test preparation and the reference preparation in healthy Chinese subjects; 2) To evaluate the skin reactivity of the test preparation and the reference preparation in healthy Chinese subjects.

Primary objective: This study used Esomeprazole Magnesium Enteric-coated Capsules (Specification: 40 mg) produced by Qingdao Baiyang Pharmaceutical Co., Ltd. as the test preparation and Esomeprazole Magnesium Enteric-coated Capsules (Specification: 40 mg; Nexium®) produced by AstraZeneca Pharmaceuticals LP as the reference preparation for bioequivalence testing to evaluate the bioequivalence of the test preparation and the reference preparation when administered under fasting, fasting applesauce spreading conditions, and postprandial conditions. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Primary objective: To demonstrate the bioequivalence of the test formulation (T): memantine hydrochloride extended-release capsules 28 mg and the reference formulation (R): NAMENDA XR® (memantine hydrochloride) extended-release capsules 28 mg in normal healthy adult subjects after taking a meal. Secondary objective: To monitor the safety and tolerability of a single oral dose of the test drug.